Programming HIV/AIDS: a human rights approach – A tool for international development and community-based organizations responding to HIV/AIDS (Canadian version)

The tool was prepared with reference to Government of Canada policies and practices, and the primary audience is program staff in Canada in non-governmental development organizations community based AIDS organizations the private sector who prepare funding proposals, and manage and evaluate projects or programs, which address HIV/AIDS and related issues in developing countries and countries … Read more

Controlling Drug Costs for People Living with HIV/AIDS: Federal Regulation of Pharmaceutical Prices in Canada

The paper: highlights the significance of policy on pharmaceutical pricing, given increasing costs and spending on medicines as part of overall healthcare spending in Canada; identifies recent developments that are important because they inform current debates in Canada over regulating drug prices, or our policies in general relating to pharmaceuticals; outlines current federal law and … Read more

HIV/AIDS and Pharmaceutical Pricing

This info sheet is one in a series of seven info sheets on the federal regulation of pharmaceutical prices in Canada. Health Spending and the Pharmaceutical Industry Controlling Medicine Prices: Evolution of Canadian Law Patented Medicine Prices Review Board Preventing Excessive Pricing of Patented Medicines Jurisdiction of the PMPRB Pricing of HIV/AIDS Drugs Trends in … Read more

Letter to the Standing Committee on Industry, Science and Technology re: Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act

“I write to follow up on our previous submissions to the Standing Committee regarding Bill C-9, Canada’s laudable initiative to implement the WTO General Council Decision of August 30, 2003 to enable countries lacking sufficient pharmaceutical manufacturing capacity to ‘make effective use’ of compulsory licensing to obtain lower cost generic pharmaceutical products manufactured in Canada…”